Vensica Medical
Misgav
About Vensica Medical
Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica’s device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $33.2M
- Last round: Series Unknown (Oct 2024)
- Website: vensica.com
- Phone: +119179638694
Industries & Categories
Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vensica-medical-46527 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.